GSK share price: a bargain for my ISA?

The GSK share price is 12% cheaper than it was at the start of the year. 6% dividend yields have me eyeing this FTSE 100 giant very closely indeed.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE:GSK) has had some positive headlines recently, adding momentum to the GSK share price growth in recent days. 

The multinational FTSE 100-listed pharma has been contracted by the UK government to help manufacture 60m doses of the Novavax Covid-19 vaccine. 

And yet the shares are trading 12% lower than 12 months ago. Could these be the perfect buy for my Stocks and Shares ISA when allowances reset in April? 

GSK share price: bargain?

Investing themes tend to come along in waves. At one point, the stock market will be overly optimistic about the prospects of growth companies. At other times the market will be unduly pessimistic about the future fortunes of dividend payers like GSK. 

The father of value investing and Warren Buffett’s mentor, Benjamin Graham, described the phenomenon like this. He wrote: “Price fluctuations have only one significant meaning for the true investor. They provide him with an opportunity to buy wisely when prices fall sharply and sell wisely when they advance a great deal.”

So is it time for me to “buy wisely” with the GSK share price having fallen sharply in the last 12 months? 

Future split 

The main risks on the horizon for me when I look at the GSK share price are the dividend and the planned split of the company. CEO Emma Walmsley is spearheading the division of GSK into two separate companies. One will focus on biopharma and drug development. The other will cover GSK’s consumer healthcare business. 

Its biopharma division continues to pump out news at a fair old clip. This covers developments in everything from HIV drugs to asthma treatments and monoclonal antibody antiviral remedies for Covid-19. I’m not so sure about the consumer healthcare arm. 

The moat is everything

I’m very much a fan of businesses with strong economic moats. When I look to buy income-producing shares for my ISA, I want to know those companies have market-leading positions. That’s so they can continue to dominate the market and produce healthy profits for years to come.

By 2026, GSK plans to double the number of market-leading ‘blockbuster’ drugs in its portfolio. To me, that means an even stronger moat. And given the company’s laundry list of trademarks and patents on its drugs, I see the GSK share price remaining fairly buoyant long term.

Higher profits also generally means a stronger chance that dividends will continue unabated. 

At today’s share price around 1300p, an 80p annual dividend represents a 6.1% yield. That’s among the best of what the FTSE 100 can offer. 

Analysts generally believe the GSK share price can support a 67p dividend going forward. Even at these lower levels that represents a 5.1% yield, far above the FTSE 100’s 2.3% average.

In conclusion

FY2020 results released in February 2021 showed me a resilient business that performed well during the pandemic. However, earnings per share are expected to decline in by a mid to high single digit percentage in 2021. It’s down to the cost of investing in the company’s drug pipeline. So investors could see the GSK share price fall further.

But I think a higher capex is a good trade off for improved margins.

Walmsley has hit £300m cost saving targets and with the 2022 split on track? I can believe her statement that shareholders should expect “meaningful improvement in revenues and margins“. I’m buying. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

TomRodgers has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »